SARS-CoV-2 spike in complex with LCB1 (local refinement of the RBD and LCB1)

Seattle Structural Genomics Center for Infectious Disease (SSGCID)

alpha-L-fucose; 6-deoxy-alpha-L-galactopyranose; L-fucose; fucose

N-acetyl-beta-D-glucosamine; 2-acetamido-2-deoxy-beta-D-glucose; 2-acetamido-2-deoxy-D-glucose; 2-acetamido-2-deoxy-glucose; N-ACETYL-D-GLUCOSAMINE

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.

Severe acute respiratory syndrome coronavirus 2

Seattle Structural Genomics Center for Infectious Disease

National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

SARS-CoV-2, COVID-19, spike glycoprotein, fusion protein, neutralizing antibodies, Structural Genomics, Seattle Structural Genomics Center for Infectious Disease, SSGCID, Inhibotor, VIRAL PROTEIN